Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC)

MLA

Jennifer Jackson, et al. “Characterization of Tumor Mutational Burden (TMB), PD-L1, and DNA Repair Genes to Assess Correlation with Immune Checkpoint Inhibitors (ICIs) Response in Metastatic Renal Cell Carcinoma (MRCC).” Journal of Clinical Oncology, vol. 37, May 2019, p. e16079. EBSCOhost, https://doi.org/10.1200/jco.2019.37.15_suppl.e16079.

APA

Jennifer Jackson, Shannon J. McCall, Daniel J. George, Tian Zhang, Peter Simone, John K. Simmons, James R. White, Matthew Labriola, Jason Zhu, Eric Kong, Elizabeth Weingartner, Kelly Gerding, Rajan T. Gupta, & Eniko Papp. (2019). Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology, 37, e16079. https://doi.org/10.1200/jco.2019.37.15_suppl.e16079

Chicago

Jennifer Jackson, Shannon J. McCall, Daniel J. George, Tian Zhang, Peter Simone, John K. Simmons, James R. White, et al. 2019. “Characterization of Tumor Mutational Burden (TMB), PD-L1, and DNA Repair Genes to Assess Correlation with Immune Checkpoint Inhibitors (ICIs) Response in Metastatic Renal Cell Carcinoma (MRCC).” Journal of Clinical Oncology 37 (May): e16079. doi:10.1200/jco.2019.37.15_suppl.e16079.